Physician profile
John D Voss
NPI 1780793059
$21,187.59
in general payments reported to CMS, 2019-2025
80 companies · $3,607 in 2025
The $3,607 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,600 · 2020: $2,372 · 2021: $2,870 · 2022: $3,425 · 2023: $3,030 · 2024: $3,284 · 2025: $3,607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,673 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,673.24 |
| Education | $247.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,557.95 | 2019-2025 | Erleada, Akeega, Darzalex |
| Astrazeneca Pharmaceuticals Lp | $1,484.91 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Merck Sharp & Dohme LLC | $1,366.99 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $1,134.35 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $979.44 | 2019-2025 | Opdivo, Opdualag |
| Pfizer INC. | $940.55 | 2019-2025 | |
| Genzyme Corporation | $807.28 | 2019-2025 | |
| Amgen INC. | $745.69 | 2019-2023 | Lumakras, Kyprolis |
| Incyte Corporation | $683.51 | 2019-2025 | Jakafi, Monjuvi, Niktimvo |
| Celgene Corporation | $615.73 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Genentech USA, INC. | $614.30 | 2019-2025 | Polivy, Venclexta, Itovebi |
| Abbvie INC. | $598.49 | 2019-2025 | Venclexta |
| Takeda Pharmaceuticals U.S.A., INC. | $522.64 | 2019-2025 | Fruzaqla, Ninlaro, Iclusig |
| Gilead Sciences, INC. | $441.06 | 2019-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $436.47 | 2019-2025 | Libtayo |
Show all 80 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $426.64 | 2019-2025 | Xtandi, Vyloy, Xospata |
| Daiichi Sankyo INC. | $389.43 | 2020-2025 | Enhertu, Datroway |
| Beigene USA, INC. | $368.65 | 2020-2024 | Brukinsa |
| Eisai INC. | $359.93 | 2019-2025 | |
| Lilly USA, LLC | $349.19 | 2019-2024 | Jaypirca, Verzenio, Retevmo |
| Exelixis INC. | $320.68 | 2019-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $302.24 | 2019-2025 | |
| Glaxosmithkline, LLC. | $288.69 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Tosoh Bioscience, INC. | $279.00 | 2019 | |
| Emd Serono, INC. | $275.32 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $261.10 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Pharmacyclics LLC, An Abbvie Company | $257.37 | 2019-2023 | Imbruvica |
| Puma Biotechnology, INC. | $252.03 | 2019-2025 | |
| Kite Pharma, INC. | $235.78 | 2020-2023 | Yescarta |
| Karyopharm Therapeutics INC. | $230.55 | 2020-2025 | Xpovio |
| Myriad Genetic Laboratories, INC. | $227.55 | 2021-2023 | Bracanalysis Cdx |
| Jazz Pharmaceuticals INC. | $226.00 | 2020-2025 | Zepzelca |
| Array Biopharma INC | $181.24 | 2020-2025 | Braftovi, Mektovi, Tukysa |
| Sanofi-Aventis U.S. LLC | $176.54 | 2019-2021 | |
| Taiho Oncology, INC. | $172.84 | 2019-2025 | |
| Seagen INC. | $172.32 | 2020-2023 | Adcetris |
| Beone Medicines USA, INC. | $148.36 | 2025 | Brukinsa, Tevimbra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.34 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $128.53 | 2022-2025 | Fotivda |
| Blueprint Medicines Corporation | $125.67 | 2020-2022 | |
| Genmab U.S., INC. | $123.76 | 2023-2025 | Tivdak, Epkinly |
| Stemline Therapeutics INC. | $120.10 | 2023-2025 | Orserdu |
| G1 Therapeutics, INC. | $112.57 | 2022-2023 | Cosela |
| Acceleron Pharma, INC. | $107.53 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $106.40 | 2019-2022 | |
| Pharmaessentia USA Corporation | $102.86 | 2022-2025 | Besremi |
| Morphosys, US INC. | $102.04 | 2021-2023 | Monjuvi |
| Coherus Oncology, INC. | $94.32 | 2020-2024 | |
| Pharmacosmos Therapeutics INC. | $88.01 | 2021-2024 | Cosela |
| Springworks Therapeutics, INC. | $76.49 | 2024-2025 | Ogsiveo |
| Octapharma USA, INC. | $70.60 | 2020 | |
| Spectrum Pharmaceuticals INC. | $65.79 | 2025 | Rolvedon |
| Tersera Therapeutics LLC | $59.15 | 2021-2023 | Zoladex |
| Agios Pharmaceuticals, INC. | $54.12 | 2019-2025 | Pyrukynd |
| Adc Therapeutics America, INC. | $53.17 | 2021-2023 | |
| Kyowa Kirin, INC. | $46.21 | 2021 | |
| Legend Biotech USA INC. | $45.47 | 2025 | Carvykti |
| Secura Bio, INC. | $43.45 | 2020-2022 | |
| Dova Pharmaceuticals | $36.30 | 2021 | |
| Verastem, INC. | $35.97 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $35.22 | 2019-2020 | |
| Tesaro, INC. | $33.71 | 2019 | |
| Alexion Pharmaceuticals, INC. | $32.22 | 2022 | |
| Janssen Scientific Affairs, LLC | $28.35 | 2024 | Tecvayli, Darzalex |
| Sun Pharmaceutical Industries INC. | $28.22 | 2023 | Odomzo, Yonsa |
| Clovis Oncology, INC. | $24.77 | 2019-2020 | |
| Sanofi US Services INC. | $22.45 | 2025 | |
| Janssen Pharmaceuticals, INC | $22.26 | 2019-2020 | |
| Tg Therapeutics, INC. | $20.92 | 2021 | |
| Dendreon Pharmaceuticals LLC | $19.43 | 2025 | Provenge |
| Sobi, INC | $19.21 | 2023 | |
| Mirati Therapeutics, INC. | $18.74 | 2023 | Krazati |
| Immunomedics, INC. | $18.12 | 2020 | |
| Caris Mpi, INC. | $17.79 | 2025 | Mi Cancer Seek |
| Novocure INC. | $17.65 | 2024 | Optune Lua (Novottf-200t) |
| Geron Corporation | $17.05 | 2025 | Rytelo |
| Fresenius Kabi USA, LLC | $16.02 | 2025 | Stimufend |
| Aurobindo Pharma USA, INC. | $13.22 | 2020 | |
| Deciphera Pharmaceuticals INC. | $11.44 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
Keytruda $773Erleada $438Enhertu $404Lynparza $389Libtayo $354Imfinzi $324Opdivo $314Sarclisa $296Reblozyl $265Venclexta $249Lenvima $213Akeega $212Xtandi $210Pluvicto $209Brukinsa $197Tukysa $192Bracanalysis Cdx $182Kisqali $173Cabometyx $171Fruzaqla $169Darzalex $164Trodelvy $161Jakafi $159Ibrance $158Polivy $153Monjuvi $149Imbruvica $143Cosela $140Zejula $138Jemperli $138Tecvayli $134Scemblix $132Xpovio $129Rezlidhia $125Tavalisse $125Talzenna $122Orgovyx $121Adcetris $121Jaypirca $121Orserdu $120Lutathera $118Rybrevant $111Ninlaro $110Inqovi $110Lonsurf $110Fotivda $107Braftovi $106Epkinly $102Zepzelca $98.75Vitrakvi $92.48Stivarga $92.48Balversa $86.89Mektovi $86.83Besremi $84.90Welireg $82.61Verzenio $72.84Tivdak $72.74Elrexfio $66.84Rolvedon $65.79Vyloy $60.71Ogsiveo $58.29Nubeqa $55.52Xospata $51.67Talvey $50.11Iclusig $50.02Ojjaara $49.05Opdualag $47.26Bosulif $45.62Jevtana $45.59Carvykti $45.47Nerlynx $42.51Tevimbra $41.50Elahere $41.23Tasigna $38.41Niktimvo $37.28Pomalyst $36.84Tagrisso $36.39Paxlovid $36.22Yescarta $34.47Xofigo $33.90Xalkori $32.71Lorbrena $32.71Itovebi $29.40Loqtorzi $28.32Yonsa $28.22Odomzo $28.22Datroway $27.88Ziihera $26.83Ayvakit $25.74Padcev $25.33Mekinist $24.41Zoladex $23.84Udenyca $22.68Gavreto $21.99Tecentriq $21.25Alunbrig $20.38Piqray $19.99Provenge $19.43Comirnaty $19.25Doptelet $19.21
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Voss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.